Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Across the recent three months, 10 analysts have shared their insights on Incyte (NASDAQ:INCY), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 0 | 7 | 0 | 0 |
Last 30D | 0 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 1 | 0 | 0 |
2M Ago | 1 | 0 | 3 | 0 | 0 |
3M Ago | 2 | 0 | 3 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Incyte, presenting an average target of $70.8, a high estimate of $84.00, and a low estimate of $64.00. This current average has decreased by 1.21% from the previous average price target of $71.67.
In examining recent analyst actions, we gain insights into how financial experts perceive Incyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Brian Abrahams | RBC Capital | Maintains | Sector Perform | $65.00 | - |
Tazeen Ahmad | B of A Securities | Lowers | Neutral | $67.00 | $69.00 |
Stephen Willey | Stifel | Maintains | Hold | $68.00 | - |
Brian Abrahams | RBC Capital | Maintains | Sector Perform | $65.00 | - |
Kelly Shi | Jefferies | Announces | Buy | $81.00 | - |
Evan Seigerman | BMO Capital | Raises | Market Perform | $64.00 | $58.00 |
David Lebowitz | Citigroup | Lowers | Buy | $81.00 | $82.00 |
Brian Abrahams | RBC Capital | Raises | Sector Perform | $65.00 | $63.00 |
Stephen Willey | Stifel | Raises | Hold | $68.00 | $67.00 |
Srikripa Devarakonda | Truist Securities | Lowers | Buy | $84.00 | $91.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Incyte's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Incyte analyst ratings.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Incyte displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 9.35%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 19.84%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Incyte's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.97%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 3.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INCY